Market cap
₹1,338 Cr
Revenue (TTM)
₹57 Cr
P/E Ratio
60.7
P/B Ratio
--
Div. Yield
0 %
Quality Score
4/10
Growth Score
4/10
Valuation Score
4/10
Momentum Score
10/10
Stock Range
Today’s Range
52 Week Range
Liquidity
Fundamentals
-
Net Profit (TTM)
₹22 Cr
-
ROE
15.9 %
-
ROCE
21.8 %
-
Industry P/E
42.28
-
EV/EBITDA
--
-
Debt to Equity
0
-
Book Value
₹2
-
EPS
₹0.5
-
Face value
1
-
Shares outstanding
439,614,440
10 Years Aggregate
CFO
₹19.18 Cr
EBITDA
₹49.28 Cr
Net Profit
₹35.10 Cr
Performance
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Shukra Pharma
| -48.6 | -3.1 | -24.0 | 116.7 | 84.4 | 149.8 | 59.4 |
|
BSE Healthcare
| 9.3 | 0.6 | 11.8 | 9.5 | 23.7 | 13.8 | 12.3 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Shukra Pharma
| 313.9 | 349.7 | 349.9 | 58.5 | 94.6 | -20.1 | 15.1 |
|
BSE Small Cap
| -6.6 | 29.0 | 47.5 | -1.8 | 62.8 | 32.1 | -6.8 |
|
BSE Healthcare
| -3.3 | 43.1 | 37.0 | -12.1 | 20.9 | 61.4 | -3.5 |
Essential Checks
View DetailsIs there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
Financials
View DetailsKey Ratios
View Details
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Peers
View DetailsCompany |
Price (₹) | Market Cap (₹ Cr) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Shukra Pharma
|
30.4 | 1,338.2 | 56.7 | 22.1 | 44.6 | 28.3 | 60.7 | -- |
| 3,136.3 | 25,674.8 | 1,339.4 | 356.4 | 33.2 | 23.2 | 72.1 | 15.5 | |
| 413.8 | 15,838.3 | 2,268.6 | 150.1 | 10.6 | 5.4 | 88.4 | 4.0 | |
| 782.1 | 19,386.4 | 5,365.6 | 595.0 | 16.6 | 13.3 | 32.6 | 3.8 | |
| 973.5 | 15,523.5 | 8,279.6 | 397.8 | 9.9 | 6.4 | 39 | 2.2 | |
| 883.5 | 15,819.9 | 4,078.3 | 1,371.9 | 30.2 | 15.9 | 11.2 | 1.7 | |
| 1,651.2 | 18,922.3 | 1,421.6 | -73.8 | 1.8 | -1.1 | -- | 3.2 | |
| 160.2 | 21,328.2 | 8,869.1 | -383.1 | 1.0 | -4.2 | -- | 2.6 | |
| 440.3 | 17,777.6 | 3,738.7 | 316.7 | 12.5 | 7.5 | 56.1 | 3.7 | |
| 1,989.2 | 32,323.8 | 3,373.0 | 199.0 | 12.6 | 5.9 | 151.8 | 6.5 |
Shareholding Pattern
View DetailsNews & Analysis
All NewsNo Review & Analysis are available.
About Shukra Pharma
Manufacture of allopathic pharmaceutical preparations
-
Incorporated
1993
-
Chairman
--
-
Managing Director
Dakshesh Rameshchandra Shah
-
Headquarters
Ahmedabad, Gujarat
-
Website
Annual Reports
Announcements
View AnnouncementsNotice Of EGM To Be Held On 6Th July 2026
12-Jun-2026Corporate Action-Board approves Dividend
07-May-2026Regulation 32 For Starement Of Deviation
07-May-2026No News & Announcements are available.
FAQs for Shukra Pharma
What is the current share price of Shukra Pharmaceuticals Ltd Today?
The share price of Shukra Pharmaceuticals Ltd is ₹30.44 (BSE) as of 18-Jun-2026 IST. Shukra Pharmaceuticals Ltd has given a return of 84.44% in the last 3 years.
What is the current PB & PE ratio of Shukra Pharmaceuticals Ltd?
The P/E ratio of Shukra Pharmaceuticals Ltd is 60.67 times as on 18-Jun-2026, a 43 premium to its peers’ median range of 42.28 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
99.91
|
15.23
|
|
2024
|
0.48
|
6.20
|
|
2023
|
1.04
|
0.73
|
|
2022
|
2.62
|
0.58
|
|
2021
|
7.71
|
0.45
|
What is the 52 Week High and Low of Shukra Pharmaceuticals Ltd?
The 52-week high and low of Shukra Pharmaceuticals Ltd are Rs 65.26 and Rs 12.97 as of 19-Jun-2026.
What is the market cap of Shukra Pharmaceuticals Ltd?
Shukra Pharmaceuticals Ltd has a market capitalisation of ₹ 1,338 Cr as on 18-Jun-2026. As per SEBI classification, it is a Small Cap company.
Should I invest in Shukra Pharmaceuticals Ltd?
Before investing in Shukra Pharmaceuticals Ltd, assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.